Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDOSTAR continuous intravenous infusion plus AP or GP versus AP or GP alone as first-line treatment for driver gene-negative advanced non-small cell lung cancer
ChiCTR1900024622Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of endostar in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC) and Pulmonary squamous cell carcinoma (4 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900024622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024622.